Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Esophageal squamous cell carcinoma (ESCC) has limited treatment options post-immune checkpoint inhibitor (ICI) resistance. We developed IPM514, a universal multi-epitope mRNA lipid nanoparticle (LNP) vaccine targeting tumor-associated antigens identified via transcriptomic analysis of TCGA/GTEx datasets and validated in 132 ESCC patients. IPM514 contains 15 fragments from 9 antigens, covering most patients and over half of HLA subtypes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
